VYNE Therapeutics Reports Positive Phase 1a MAD Data for VYN202

VYNE Therapeutics Inc., a Delaware-based biopharmaceutical company, recently disclosed significant developments in its clinical trials concerning VYN202, a novel BD2-Selective BET Inhibitor. The company issued a press release on December 23, 2024, highlighting positive top-line Phase 1a MAD (Multiple Ascending Dose) data for the experimental compound. The Phase 1a trial results indicated that VYN202 exhibited […]

Leave a Reply

Your email address will not be published.

Previous post Raymond James Issues Positive Forecast for Payfare (TSE:PAY) Stock Price
Next post Drake Maye, Jacoby Brissett to reward Patriots O-line with Christmas gifts